Secoisolariciresinol Diglucoside
|
|
| Compound | Secoisolariciresinol Diglucoside |
| Animal species | human intestinal bacteriahuman intestinal bacteria Peptostreptococcus sp. SDG-1human intestinal bacteria Eubacterium sp. SDG-2 |
| Metabolism parameters | |
| Metabolites |
Secoisolariciresinol Diglucoside
Secoisolariciresinol 4-((2S,3S)-4-hydroxy-3-(4-hydroxy-3-methoxybenzyl)-2-(hydroxymethyl)butyl)benzene-1,2-diol 04 4,4'-((2S,3S)-2,3-bis(hydroxymethyl)butane-1,4-diyl)dibenzene-1,2-diol 4-((2S,3S)-4-hydroxy-3-(3-hydroxybenzyl)-2-(hydroxymethyl)butyl)benzene-1,2-diol (2S,3S)-2,3-bis(3-hydroxybenzyl)butane-1,4-diol (+)-Enterolactone |
| Crude drug | |
| References | 1) Wang L., Meselhy M. R., Li Y., Qin G., and Hattori M., Human intestinal bacteria capable of transforming secoisolariciresinol diglucoside to mammalian lignans, enterodiol and enterolactone. Chem. Pharm. Bull., 48, 1606-1610 (2000). 2) Gao J. J. and Hattori M.: Metabolic activation of lignans to estrogenic and anti-eatrogenic substances by human intestinal bacteria. J. Trad. Med., 22, 213-221 (2005). |
| Remarks | Incubation of secoisolariciresinol diglucoside (1) with a human fecal suspension Secoisolariciresinol diglucoside (1, 300 mg) dissolved in PYF broth (250 ml) was incubated with a human fecal suspension (50 ml) at 37°C in an anaerobic incubator for 15 h. [Wang et al., Chem. Pharm. Bull., 48, 1606-1610 (2000)] |
